ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
September 22 2021 - 4:01PM
Business Wire
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced the appointment of Helen M. Thackray, MD, FAAP to
its Board of Directors.
"Helen joins ImmunoGen's Board of Directors at an exciting time,
as we advance multiple programs in the clinic and transform
ImmunoGen into a fully integrated oncology company with the
potential to launch two innovative ADCs next year," said Stephen
McCluski, ImmunoGen's Chairman of the Board of Directors. "Her deep
development and regulatory expertise will be invaluable in the near
term, as we anticipate pivotal data and submission of a BLA for our
lead program, mirvetuximab soravtansine, and progress the rest of
our portfolio with a focus on a path to full approval for IMGN632
in blastic plasmacytoid dendritic cell neoplasm (BPDCN)."
Dr. Thackray has over 25 years of biopharmaceutical, clinical
research, and bench research experience. Currently, Dr. Thackray is
the Chief Research and Development Officer for BioCryst
Pharmaceuticals, Inc., where she oversees research and development
activities from discovery through registration and defines the
strategic direction of the Company's pipeline. Prior to joining
BioCryst, Dr. Thackray served in various positions of increasing
responsibility at GlycoMimetics, Inc., including ten years as Chief
Medical Officer and Senior Vice President, Clinical Development. In
this role, she led product development for a multinational program
in AML (acute myeloid leukemia) and other hematologic malignancies
from pre-IND through registration studies. Earlier in Dr.
Thackray's career, she was Vice President, Clinical Product
Development for Biosynexus, Inc., where she led the Company's
development programs in orphan indications. Dr. Thackray is a
board-certified pediatrician and, since 2002, has been an Assistant
Clinical Professor in Pediatrics at George Washington University
School of Medicine and Health Sciences. She holds a Doctor of
Medicine degree from George Washington University, School of
Medicine and Health Sciences, a Bachelor of Sciences degree from
Stanford University, and is a Fellow of the American Academy of
Pediatrics (FAAP).
Dr. Thackray stated, "ImmunoGen has established a leadership
position in ADCs and built a strong pipeline targeting solid tumors
and hematologic malignancies. The Company is rapidly approaching
the commercialization of two products in areas of significant unmet
need, and I look forward to contributing my expertise and working
with the rest of the Board and management team to deliver more good
days for cancer patients and create long-term value for the
business."
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD-LOOKING STATEMENTS This press release includes
forward-looking statements based on management's current
expectations. These statements include, but are not limited to,
ImmunoGen's expectations related to: the occurrence, timing, and
outcome of potential preclinical, clinical, and regulatory events
related to the Company's product candidates, in particular with
respect to mirvetuximab soravtansine and IMGN632, and the launch of
those product candidates next year; and the presentation of
preclinical and clinical data on the Company's product candidates,
including with respect to mirvetuximab soravtansine and IMGN632.
For these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. Various factors could
cause ImmunoGen's actual results to differ materially from those
discussed or implied in the forward-looking statements, and you are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this release.
Factors that could cause future results to differ materially from
such expectations include, but are not limited to: the timing and
outcome of the Company's preclinical and clinical development
processes; the difficulties inherent in the development of novel
pharmaceuticals, including uncertainties as to the timing, expense,
and results of preclinical studies, clinical trials, and regulatory
processes; the Company's ability to financially support its product
programs; risks and uncertainties associated with the scale and
duration of the COVID-19 pandemic and the resulting impact on
ImmunoGen's industry and business; and other factors as set forth
in the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 1, 2021, and other
reports filed with the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210922005713/en/
INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtney
O'Konek 781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024